文献速递胸部肿瘤消化系统肿瘤

SHERPA试验:SHP2抑制剂RMC-4630联合ERK抑制剂LY3214996治疗KRAS突变胰腺癌、非小细胞肺癌和结直肠癌的I期研究

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.
PubMed 文献 · Eur J Cancer · 2026-05-06

SHERPA是一项I期剂量递增试验,评估SHP2抑制剂RMC-4630联合ERK抑制剂LY3214996在KRAS突变胰腺癌、非小细胞肺癌或结直肠癌患者中的安全性。药效学分析显示磷酸化S6核糖体蛋白显著下降(p=0.034),但未观察到影像学缓解。

要点

  • RMC-4630联合LY3214996在三个剂量水平出现DLT,剂量递增终止,RP2D未确定。
  • DLT包括3级血小板减少、2级左心室射血分数下降、3级急性肾损伤和腹泻。
  • 药效学显示pS6显著下降(p=0.034),但无影像学缓解,未达到充足暴露。

核心结论

  • RMC-4630联合LY3214996因毒性特征未能达到充足暴露,剂量递增终止,RP2D未确定。
  • 在探索的剂量水平未观察到肿瘤缓解。

主要发现

  • 四个探索剂量水平中有三个报告DLT,阻止进一步递增。
  • DLT包括3级血小板减少(3例)、2级左心室射血分数下降、3级急性肾损伤和腹泻。
  • 剂量水平1b(RMC-4630 100 mg;LY3214996 200 mg)未报告DLT。
  • 药代动力学显示高个体间变异和个体内暴露相关性,未建立暴露-毒性关系。
  • 药效学显示磷酸化S6核糖体蛋白显著下降(p=0.034),但未观察到影像学缓解。

临床怎么用

  • 该联合方案在探索剂量下未显示可接受的毒性特征和抗肿瘤活性,不支持进一步临床开发。

局限性

  • 未达到充足药物暴露,无法确定RP2D,限制了疗效评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: PDAC has high mortality rates and limited treatment options. KRAS mutations are present in > 90% of patients with PDAC, causing constitutive activation of the MAPK pathway. Preclinical studies demonstrated synergistic antitumor activity in in vivo and in vitro KRAS-mutant PDAC models by combining SHP2 and ERK inhibition. Therefore, the safety of combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 was evaluated in this phase I trial. METHODS: The aim was defining the recommended phase 2 dose (RP2D) using a 3 + 3 dose-escalation design. Second, pharmacokinetics and pharmacodynamics were explored. RESULTS: Twenty-four patients with KRASm PDAC, NSCLC or CRC were treated with RMC-4630 weekly on days 1-2 and LY3214996 daily in 28-day cycles; nineteen were evaluable for dose-limiting toxicities (DLT). DLTs were reported at three of the four explored dose levels, preventing further escalation. Three DLTs were due to grade 3 thrombocytopenia. The other three resulted from grade 2 decreased left ventricular ejection fraction, and grade 3 acute kidney injury and diarrhea. At dose level 1b (100 mg RMC-4630; 200 mg LY3214996), no DLTs were reported. Pharmacokinetic analysis revealed high interpatient variability and intrapatient correlation with exposure to both agents. An exposuretoxicity relationship was not established. Pharmacodynamic analysis showed a significant decrease in phosphorylated S6-ribosomal protein (p = 0.034), however radiological responses were not observed. DISCUSSION: Sufficient exposure to RMC-4630 and LY3214996 was not reached due to the toxicity profile of the combination. Tumor response was not demonstrated at the explored dose levels. Therefore, the dose escalation was discontinued, and the RP2D was not determined.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kanhailal AC, Knikman JE, Zielhuis SWJ, et al. The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer. Eur J Cancer. 2026. PMID: 42114409. doi:10.1016/j.ejca.2026.116782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。